Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

Posted by Leslie Small on May 12, 2020

Since acquiring Aetna, CVS Health Corp. has touted its HealthHUB stores — which include expanded clinics, labs for health screening and space for wellness pursuits — as the linchpin of its plan to stand out among other large, diversified firms that include a health insurer. Yet as one analyst pointed out during CVS’s first-quarter 2020 earnings call on May 6, that strategy could face new challenges amid the COVID-19 pandemic when many people are reluctant to venture outside their homes.

CVS executives said that while the company is indeed seeing less foot traffic at its brick-and-mortar locations, it is still leveraging the power of having a vast retail footprint by offering testing for the new coronavirus, AIS Health reported.

Read More

Topics: Industry Trends, Data & Analytics, Provider, Payer

Trends That Matter for Biosimilar Medications Cost Savings

Posted by Peter Johnson on May 7, 2020

Biosimilar medications can offer meaningful cost savings for payers, but market and regulatory barriers are still preventing them from realizing their full economic potential, according to a March 31 Johns Hopkins University study funded by the ERISA Industry Committee.

"We could see and empirically prove that patients…tended to be better off if they were on the biosimilar," Mariana Socal, a physician and researcher at the Johns Hopkins Bloomberg School of Public Health and one of the study's authors, tells AIS Health. "They had lower out-of-pocket costs when they were on the biosimilar."
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19

Posted by Peter Johnson on Apr 30, 2020

The COVID-19 pandemic is shaping up to be a stress-test for the post-Affordable Care Act insurance market. The crisis has already caused mass layoffs, and experts say the individual health insurance exchanges and Medicaid could see record enrollment in the coming months as a result, AIS Health reported.

“This would be the first recession since the Affordable Care Act went into effect, so we are in somewhat uncharted territory in terms of what might happen in a recession under both the ACA marketplace and the Medicaid expansion,” Larry Levitt, executive vice president for health policy at the Kaiser Family Foundation, said during a March 18 conference call with reporters.
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19

Posted by Leslie Small on Apr 28, 2020

Newly released data from Express Scripts shows that the number of prescriptions filled per week for antidepressants, anti-anxiety and anti-insomnia medications combined jumped 21% between mid-February and mid-March — reaching a zenith during the week ending March 15, when the COVID-19 outbreak officially reached pandemic status. And analytics from UnitedHealth Group's OptumRx showed prescription increases of 15% for anti-anxiety medications, 14% for antidepressants and 5% for anti-insomnia medications during the month of March.

Industry consultants tell AIS Health that they're not at all surprised that the use of such medications is spiking. And they say that situation creates an urgent opportunity for companies that combine a health insurer with a PBM — like Express Scripts parent company Cigna Corp. and its peers — to leverage their unique insights into members' health.

Read More

Topics: Industry Trends, Data & Analytics, Provider, Payer

Trends That Matter for Bipolar Disorder Medications

Posted by Bronwyn Mixter on Apr 23, 2020

A recently approved brand drug for bipolar disorder will have little impact on how health plans cover these medications, experts tell AIS Health. Health plans will continue to encourage the use of less expensive generic bipolar drugs.

The brand drug, Allergan plc's Vraylar (cariprazine), was approved by the FDA to treat depressive episodes associated with bipolar 1 disorder in adults. It is an oral, once-daily atypical antipsychotic.
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth

Posted by Lauren Flynn Kelly on Apr 23, 2020

As the COVID-19 pandemic continues to dominate the news cycle, headlines related to rising unemployment often underscore the impact to Medicaid, but what about the Medicaid managed care organizations that will absorb the newly jobless and uninsured?

"I think that Medicaid MCOs are clearly in the best position to handle the influx of folks," remarks Jerry Vitti, founder and CEO of Healthcare Financial, Inc. While onboarding a wave of new members may put some initial stress on plans, the real "strain" will come from covering new members who have unmet health care needs, he tells AIS Health.

Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing

Posted by Leslie Small on Apr 21, 2020

With the Trump administration anxious to "reopen" the U.S. economy and ease the social-distancing measures meant to slow the spread of COVID-19, officials have pointed to antibody testing as a critical tool to accomplish those goals. To that end, the administration on April 11 issued a document clarifying that most private health plans must cover such tests, which detect antibodies against the new coronavirus found in the blood of people who have been infected and now may be immune.

"It's not exactly a surprise, [but] I don’t know that it was 100% expected," Jason Karcher, a Milliman Inc. actuary, tells AIS Health regarding the requirement. "It seems like as much a point of clarification rather than a 'hey, we're going to require something totally out of the blue.'"

Read More

Topics: Industry Trends, Provider, Payer

Perspectives on COVID-19 Outbreak's Impact on Drug Supply

Posted by Peter Johnson on Apr 16, 2020

Industry experts say the COVID-19 outbreak is unlikely to limit U.S. drug supplies in the short or middle term. However, they tell AIS Health that increased demand for longer-duration stocks of medication from self-isolating patients could strain supplies going forward.

"We are told at this point that we're not seeing any [drug] shortages in the marketplace today," says Kelly McGrail-Pokuta, Prime Therapeutics' vice president of pharmaceutical trade.
 
Read More

Topics: Industry Trends, Market Access, Provider, Payer

Trends That Matter for Cost Impact of Coronavirus Treatment

Posted by Leslie Small on Apr 9, 2020

Though many health insurers have removed cost barriers related to testing patients for the new coronavirus that's sweeping the globe, they largely haven't pledged to waive out-of-pocket costs for severely sickened members who require hospitalization. A new analysis suggests that the cost of caring for those patients could be steep for members and health plans alike, but experts tell AIS Health it may be too early to say what that will actually mean for commercial insurance markets.

According to the analysis, from the Peterson Center on Healthcare and the Kaiser Family Foundation (KFF), the average total cost — combining employer-plan spending and patient out-of-pocket costs — for a pneumonia-related hospital stay "with major complications and comorbidities" was $20,292 in 2018. For a stay "with complications or comorbidities," the average cost was $13,767, and for patients without complications, the price tag was $9,763. Looking at out-of-pocket costs alone, the average cost for patients with major complications or comorbidities was $1,300.
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection

Posted by Lauren Flynn Kelly on Apr 7, 2020

As efforts to contain the outbreak of COVID-19 continue to evolve, the Trump administration on March 30 issued a series of new flexibilities aimed at increasing hospital and provider capacity. At the same time, CMS in a March 30 memo provided some respite to Medicare Advantage and Part D plans dealing with the crisis by suspending audit and quality reporting activities so that plans and states can focus on providing care to the increasing number of beneficiaries affected by the new coronavirus, AIS Health reported.

As physicians cater to patients who are or may be infected with COVID-19, and as the federal government advises adults to delay elective surgeries and nonessential procedures during the outbreak, plans are likely to face issues with reporting quality data used to determine future star ratings.

Read More

Topics: Industry Trends, Provider, Payer